Baxter International Inc.

NYSE:BAX 주식 보고서

시가총액: US$17.3b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Baxter International 관리

관리 기준 확인 2/4

Baxter International's CEO는 Joe Almeida, Jan2016 에 임명되었습니다 의 임기는 8.42 년입니다. 총 연간 보상은 $ 13.79M, 9.4% 로 구성됩니다. 9.4% 급여 및 90.6% 보너스(회사 주식 및 옵션 포함). 는 $ 19.22M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 19.22M. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 4.3 년입니다.

주요 정보

Joe Almeida

최고 경영자

US$13.8m

총 보상

CEO 급여 비율9.4%
CEO 임기8.4yrs
CEO 소유권0.1%
경영진 평균 재임 기간1.7yrs
이사회 평균 재임 기간4.3yrs

최근 관리 업데이트

Recent updates

Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29

May 30
Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29

Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

May 14
Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff

May 08

Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal

Apr 14
Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal

Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts

Feb 23

Baxter International's (NYSE:BAX) Dividend Will Be $0.29

Feb 20
Baxter International's (NYSE:BAX) Dividend Will Be $0.29

Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden

Jan 28
Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden

Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital

Jan 12
Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital

Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares

Dec 28
Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares

Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield

Dec 12

Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)

Nov 27
Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)

Is Baxter International (NYSE:BAX) A Risky Investment?

Oct 27
Is Baxter International (NYSE:BAX) A Risky Investment?

Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?

Oct 12

There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital

Sep 21
There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital

Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

Aug 23
Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

Dividend Challengers Review: Baxter International

Aug 14

Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29

Jul 25
Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29

Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet

Jul 14
Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet

Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF

Jun 12

Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture

Jun 07
Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture

Baxter International's (NYSE:BAX) Dividend Will Be $0.29

May 19
Baxter International's (NYSE:BAX) Dividend Will Be $0.29

Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29

May 05
Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29

Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price

Apr 24
Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price

Is Baxter International (NYSE:BAX) Using Too Much Debt?

Apr 03
Is Baxter International (NYSE:BAX) Using Too Much Debt?

Baxter International's (NYSE:BAX) Dividend Will Be $0.29

Feb 18
Baxter International's (NYSE:BAX) Dividend Will Be $0.29

Investors Could Be Concerned With Baxter International's (NYSE:BAX) Returns On Capital

Feb 10
Investors Could Be Concerned With Baxter International's (NYSE:BAX) Returns On Capital

Baxter International: Another YoY Earnings Decline Expected, Shares Tag Support

Feb 03

Why Baxter Is One Of My #1 2023 Bets For Healthcare/Medtech

Jan 02

An Intrinsic Calculation For Baxter International Inc. (NYSE:BAX) Suggests It's 32% Undervalued

Dec 30
An Intrinsic Calculation For Baxter International Inc. (NYSE:BAX) Suggests It's 32% Undervalued

Baxter cut to hold at Deutsche Bank on inflation pressures

Dec 15

Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

Nov 18
Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

CEO 보상 분석

Joe Almeida 의 보수는 Baxter International 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$38m

Dec 31 2023US$14mUS$1m

-US$76m

Sep 30 2023n/an/a

US$225m

Jun 30 2023n/an/a

-US$3b

Mar 31 2023n/an/a

-US$3b

Dec 31 2022US$14mUS$1m

-US$3b

Sep 30 2022n/an/a

-US$3b

Jun 30 2022n/an/a

US$876m

Mar 31 2022n/an/a

US$992m

Dec 31 2021US$16mUS$1m

US$1b

Sep 30 2021n/an/a

US$1b

Jun 30 2021n/an/a

US$1b

Mar 31 2021n/an/a

US$1b

Dec 31 2020US$16mUS$1m

US$1b

Sep 30 2020n/an/a

US$911m

Jun 30 2020n/an/a

US$924m

Mar 31 2020n/an/a

US$991m

Dec 31 2019US$14mUS$1m

US$1b

Sep 30 2019n/an/a

US$1b

Jun 30 2019n/an/a

US$1b

Mar 31 2019n/an/a

US$2b

Dec 31 2018US$16mUS$1m

US$2b

Sep 30 2018n/an/a

US$1b

Jun 30 2018n/an/a

US$795m

Mar 31 2018n/an/a

US$840m

Dec 31 2017US$15mUS$1m

US$609m

보상 대 시장: Joe 의 총 보상 ($USD 13.79M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 13.50M ).

보상과 수익: 회사가 수익성이 없는 동안 Joe 의 보상이 증가했습니다.


CEO

Joe Almeida (62 yo)

8.4yrs

테뉴어

US$13,786,671

보상

Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....


리더십 팀

이름위치테뉴어보상소유권
Jose Almeida
Chairman of the Board8.4yrsUS$13.79m0.11%
$ 19.3m
Joel Grade
Executive VP & CFOless than a yearUS$5.37m0%
$ 0
Heather Knight
Executive VP & Group President of Medical Products and Therapies1.3yrsUS$4.86m0.031%
$ 5.4m
Alok Sonig
Executive VP & Group President of Pharmaceuticals1.9yrsUS$3.87m0.0016%
$ 269.5k
Christopher Toth
Executive VP & Group President of Kidney Careless than a yearUS$9.64m0.0046%
$ 789.5k
Tobi Karchmer
Senior VP and Chief Medical & Scientific Officer1.4yrs데이터 없음데이터 없음
Charles Patel
Senior VP & Chief Information Officerno data데이터 없음데이터 없음
Clare Trachtman
Vice President of Investor Relationsno data데이터 없음데이터 없음
David Rosenbloom
Executive VP & General Counsel2.2yrsUS$5.66m0.0018%
$ 314.4k
Stacey Eisen
?Senior Vice Presidentno data데이터 없음데이터 없음
Jeanne Mason
?Executive VP & Chief Human Resources Officer7.1yrsUS$4.14m0.037%
$ 6.4m
James Borzi
Executive VP & Chief Supply Chain Officer4.4yrs데이터 없음0.0030%
$ 516.5k

1.7yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: BAX 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Jose Almeida
Chairman of the Board8.4yrsUS$13.79m0.11%
$ 19.3m
Stephen Rusckowski
Independent Directorless than a yearUS$197.82k0.0018%
$ 307.5k
Robert Parkinson
Chairman Emeritus8.4yrsUS$17.88m데이터 없음
Peter Wilver
Independent Director2.1yrsUS$349.64k0.0026%
$ 449.1k
Stephen Newman Oesterle
Independent Director7.3yrsUS$373.98k0.0055%
$ 946.7k
Patricia Morrison
Independent Director5.3yrsUS$364.98k0.0042%
$ 723.8k
Nancy Schlichting
Independent Director2.5yrsUS$363.00k0.0028%
$ 483.7k
Catherine Smith
Independent Director7.4yrsUS$367.31k0.0044%
$ 763.5k
David Shafer
Lead Independent Director2.1yrsUS$382.31k0.0026%
$ 449.1k
David Wilkes
Independent Director3.3yrsUS$357.00k0.0032%
$ 551.1k
William Ampofo
Independent Directorless than a yearUS$226.35k0.0019%
$ 333.4k
Amy Wendell
Independent Director5.3yrsUS$352.98k데이터 없음

4.3yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: BAX 의 이사회경험(평균 재직 기간 4.3 년)으로 간주됩니다.